Alto Neuroscience, Inc. (ANRO) - Dilution Analysis

10-Q filing | 32.9M shares outstanding

8-K filing: Alto Neuroscience, Inc. entered into a Securities Purchase Agreement for a private placement of 2,900,000 shares of common stock and pre-funded warrants to purchase 3,100,000 shares of common stock, anticipating gross proceeds of approximately $120.0 million. ($120.0M proceeds)

10-K filing | 28.9M shares outstanding

8-K filing: Alto Neuroscience, Inc. entered into a Securities Purchase Agreement for a private placement of 3,832,263 shares of common stock and pre-funded warrants to purchase 4,622,251 shares of common stock, anticipating gross proceeds of approximately $50.0 million. ($50.0M proceeds)

10-Q filing | 27.1M shares outstanding

8-K filing: Alto Neuroscience, Inc. entered into an Asset Purchase Agreement with Chase Therapeutics Corporation, where Alto may issue up to 5,387,353 shares of its common stock to Chase Therapeutics as Milestone Payments, representing 19.9% of the outstanding shares of Alto's common stock as of the Closing Date.

10-Q filing | 27.0M shares outstanding

10-K filing | 24.6M shares outstanding

S-3 filing: Alto Neuroscience, Inc. files an S-3 to offer common stock, preferred stock, and debt securities up to an aggregate amount of $300,000,000 from time to time.

10-Q filing | 27.0M shares outstanding

10-Q filing | 26.9M shares outstanding

8-K filing: Alto Neuroscience, Inc. entered into a convertible loan agreement with The Wellcome Trust Limited for up to approximately $11.7 million to support the Company's Phase 2b clinical trial evaluating ALTO-100 in patients with bipolar depression.

10-Q filing | 26.9M shares outstanding

S-1/A filing: This S-1/A filing registers common stock for an IPO, including an option for underwriters to purchase additional shares, and details the company's plans for the use of proceeds, risk factors, and directed share program.

S-1 filing: This is an S-1 filing for an initial public offering of common stock.